Zimmer Biomet Holdings, Inc. $ZBH Stock Position Raised by Callan Family Office LLC

Callan Family Office LLC raised its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 198.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,222 shares of the medical equipment provider’s stock after purchasing an additional 36,059 shares during the period. Callan Family Office LLC’s holdings in Zimmer Biomet were worth $4,946,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ZBH. Brighton Jones LLC purchased a new stake in shares of Zimmer Biomet during the 4th quarter worth about $204,000. Farther Finance Advisors LLC raised its stake in shares of Zimmer Biomet by 33.9% during the 1st quarter. Farther Finance Advisors LLC now owns 7,300 shares of the medical equipment provider’s stock worth $820,000 after purchasing an additional 1,849 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Zimmer Biomet by 52.4% during the 1st quarter. GAMMA Investing LLC now owns 3,502 shares of the medical equipment provider’s stock worth $396,000 after purchasing an additional 1,204 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Zimmer Biomet by 0.7% during the 1st quarter. Assenagon Asset Management S.A. now owns 28,692 shares of the medical equipment provider’s stock valued at $3,247,000 after acquiring an additional 202 shares during the last quarter. Finally, CX Institutional increased its holdings in shares of Zimmer Biomet by 7.4% during the 1st quarter. CX Institutional now owns 2,510 shares of the medical equipment provider’s stock valued at $284,000 after acquiring an additional 174 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of Zimmer Biomet stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the sale, the senior vice president owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. This trade represents a 18.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.39% of the company’s stock.

Analyst Ratings Changes

ZBH has been the topic of a number of analyst reports. Royal Bank Of Canada set a $111.00 price objective on Zimmer Biomet in a report on Friday. Raymond James Financial increased their price objective on Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a report on Friday, August 8th. Rothschild Redb raised Zimmer Biomet to a “strong-buy” rating in a report on Thursday, September 18th. Evercore ISI lowered their price objective on Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating on the stock in a report on Tuesday. Finally, Rothschild & Co Redburn initiated coverage on Zimmer Biomet in a report on Thursday, September 18th. They set a “buy” rating and a $130.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $112.67.

Zimmer Biomet Stock Performance

ZBH opened at $94.79 on Friday. The firm has a market capitalization of $18.78 billion, a P/E ratio of 23.06, a price-to-earnings-growth ratio of 2.24 and a beta of 0.67. The stock’s 50 day moving average price is $101.31 and its two-hundred day moving average price is $98.34. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. Zimmer Biomet Holdings, Inc. has a 12-month low of $89.22 and a 12-month high of $114.72.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. During the same quarter last year, the firm posted $2.01 EPS. The company’s revenue was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.36%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.